(Total Views: 486)
Posted On: 05/13/2020 10:46:51 AM
Post# of 145248
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
I think FDA delay could be to buy some time for the Rendesivir to make money in the market. i am sure Remdesivir can servive till all other player get FDA approve , right now they all in clinical phase1/2/3.
One of the tough competitors for leronlimab is Regeneron's cocktail drug which has IL-6 reducer/ inhibitor
One of the tough competitors for leronlimab is Regeneron's cocktail drug which has IL-6 reducer/ inhibitor
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)